期刊
NEUROIMAGE
卷 48, 期 1, 页码 186-190出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.neuroimage.2009.06.029
关键词
Cannabis; PET; Dopamine; Schizophrenia; THC; [11C]-raclopride
资金
- Medical Research Council, UK
- NIHR BRC
- Maudsley NHS Trust
- Institute of Psychiatry, King's College London, UK
- Medical Research Council [G0701420, G90/106, G0701003, G9817803B] Funding Source: researchfish
- MRC [G90/106, G0701003, G0701420] Funding Source: UKRI
Background: Cannabis use in early adolescence may be a risk factor for development of schizophrenia. In animals, Delta 9-tetrahydrocannabinol (THC) increases the rate of dopamine neuronal firing and release in the striatum. Thus cannabis use may increase dopamine release in the human striatum leading to vulnerability to psychosis. Aims: To investigate whether THC, the main psychoactive component of cannabis, can produce dopamine release in the human striatum. Methods: Thirteen healthy volunteers, with previous cannabis experience, underwent two [11C]-raclopride positron emission tomography (PET) scans to indirectly measure striatal dopamine levels following either 10 mg THC or placebo. Results: Although THC markedly increased psychosis-like symptoms on the Psychotomimetic States Inventory (PSI), there was no significant effect of THC on [11C]-raclopride binding. Conclusion: In the largest study of its kind so far, we have shown that recreational cannabis users do not release significant amounts of dopamine from an oral THC dose equivalent to a standard cannabis cigarette. This result challenges current models of striatal dopamine release as the mechanism mediating cannabis as risk factor for schizophrenia. (C) 2009 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据